Kodi mukutsatira nkhani za Bluebird Bio? Ngati simukutero, ndi nthawi yoti mudziwe ndikuyatsa zidziwitso zanu pazosintha zaposachedwa kwambiri za kampaniyi. Chifukwa chimapangidwa kuti chifike patali zatsopano nthawi iliyonse.
Zikuyembekezeka kuti masheya a kampaniyi akwera kwambiri popeza komiti ya alangizi ya Food and Drug Administration (FDA) idalimbikitsa kuyesedwa kuwiri kwa njira zoyeserera za majini za kampaniyi.
Chifukwa chake mwina mwawona masheya akampani akukwera ndikukwera okha. Kuti mudziwe zambiri, cholembera cha 'BLUE' chomwe mwina mwachiwona pazithunzi ndi cha kampaniyi. Chifukwa chake ngakhale msika uli wonse, omwe ali ndi kampaniyi akupeza mpumulo wofunikira kwambiri.
Zofunikira za Bluebird Bio News
Iyi ndi kampani yaku Cambridge, Massachusetts yochokera ku biotechnology yomwe imayang'ana kwambiri pakupanga njira zochiritsira zamtundu wazovuta zama genetic komanso khansa. M'mbuyomu, mankhwala ake okhawo ovomerezeka ochokera ku European Union (EU) anali Betigeglogene autotemcel yomwe imatchedwa dzina (Zynteglo).
Kukumbutsani, awa ndi mankhwala achiwiri okwera mtengo kwambiri padziko lonse lapansi omwe amawononga $1.8 miliyoni. Ndi kuthekera kochulukira kampaniyo idawona magawo ake akukwera koma anali akutsika pang'onopang'ono mpaka pano. Ndi chivomerezo cha njira ziwiri zochiritsira, zikuyembekezeka kubwezera chidaliro chotayika chamtsogolo kuchokera kwa osunga ndalama.
Ntchito zina zamapaipi za kampaniyi zikuphatikiza LentiGlobin gene therapy for Sickle cell disease ndi Cerebral Adrenoleukodystrophy. Ikugwiranso ntchito pochiza Acute Myeloid leukemia, Merkel-cell carcinoma, MAGEA4 zotupa zolimba, ndi Diffuse B-cell lymphoma yayikulu.
Kuyamba ulendo wake ngati Genetix Pharmaceuticals mu 1992 ubongo wa mamembala a bungwe la MIT Irving London ndi Philippe Leboulch, bungwe la biotechnology lidawona magawo ake akukwera mpaka $178.29 mu 2018 ndipo zitatha izi, zidatsika.
Koma ndi nkhaniyi, magawowa adakwera pafupifupi 28.7% mpaka 4.80 Lolemba 14 June 2022. Zogulitsazo zikuyenda bwino kwambiri pazaka zisanu ndi zitatu zapitazi, malinga ndi deta ya Dow Jones Market Data. Ndizofunikira kudziwa kuti magawo atsika ndi 46% chaka chino.
Kuchulukirachulukira kwamtengo kumayembekezeredwa kuchokera kumalingaliro amtundu wamankhwala opangidwa ndi biotech ndi Food and Drug Administration. Pa June 9th a Cellular, Tissue, and Gene Therapies Advisory Committee ya FDA idalimbikitsa elivadogene autotmcel kapena Eli-CEL gene therapy.
Mankhwalawa amagwiritsidwa ntchito pochiza matenda omwe amagwirizana ndi X chromosome, yomwe imayamba kugwira ntchito muubongo adrenoleukodystrophy. Lachisanu, bungwe laboma lomweli lidalimbikitsa Betibeglogene autotemcel kapena beti-cel, awa ndi chithandizo chanthawi imodzi chomwe chimapangidwira odwala beta-thalassemia.
Pambuyo pa chithandizo, sipadzakhala kufunikira kwa kuikidwa kwa maselo ofiira a magazi kwa odwala omwe akhudzidwa ndi matendawa, omwe amafunikira nthawi zonse. A FDA akuyembekezeka kupanga chigamulo chovomerezeka pa beti-cel pa 19 Ogasiti ndipo tsiku la Eli-CEL ndi 16 Seputembala chaka chino.
Kutsiliza
Ndi nkhani yabwinoyi, anthu ayamba kuchita chidwi ndi magawo a kampaniyo ndipo chifukwa chake nkhani za Bluebird Bio zikuyenda mozungulira m'malo azachuma m'misika yonse. Ziribe kanthu komwe mtengo ukupita, bluebird ikuyembekezeka kupindula kwambiri ndi malingalirowa.